Key Drivers
- Strong gross margin
- Large cash buffer
- High debt and burn
AIAI Summary
Valneva has transitioned into a commercialization‑anchored vaccine company whose valuation and survival now hinge on the binary VLA15 Phase‑3 readout (H1‑2026) and near‑term IXIARO/IXCHIQ regulatory outcomes, so treat the stock as outcomes‑driven—positively skewed by a clear Phase‑3 win with Pfizer but highly vulnerable to clinical or FDA setbacks that would force dilutive financing or asset sales.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong gross margin
- •Large cash buffer
- •High debt and burn
VALN combines healthy gross economics and a strong cash position with severe profitability losses, heavy R&D/SG&A-driven cash burn, and high leverage that undermines solvency and valuation.
Price Behavior
Key Price Behavior Insights:
- •Below last month SMA
- •Rebounds at support
- •Failed resistance tests
Price is mildly bearish—trading below its last month SMA (~$10.92) with RSI ~45, repeatedly rebounding at $10.25–$10.32 support but failing to clear $11.40–$12.00 resistance without higher volume.
Repeated rebounds from $10.25 (tested 2026-03-03 and 2026-03-20) despite weakening momentum
Sentiment & News
Key News Insights:
- •2025 audited results
- •VLA15 Phase 3
- •VLA84 licensed
Valneva finalized audited 2025 results and 2026 guidance, licensed its C. difficile program to Elaris, and flagged a VLA15 Phase 3 topline readout in H1 2026 amid governance changes and investor outreach.
Clarified financials and asset licensing reduce execution risk and cash burn while the VLA15 readout will be the primary near-term share-price catalyst
Similar Companies in Healthcare
Other companies in the same sector with AI ratings